Tuesday, November 5, 2024

SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients

Related stories

Crayon Joins AWS Generative AI Partner Innovation Alliance

Crayon announced it will work with Amazon Web Services...

Sikich announced the appointment of Ray Beste as Principal AI Strategist

Sikich, a Chicago-based leading global technology-enabled professional services company,...

Wondershare Unveils SelfyzAI 3.0: New AI Features Enhance Image Editing Experience

Wondershare proudly launched SelfyzAI 3.0, the latest version of...

Dan Muscatello Joins OneSix as Chief Revenue Officer

OneSix, a leading data and artificial intelligence (AI) consultancy...
spot_imgspot_img

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.

The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients, including individualized surgical planning, treatment, drug selection, and risk stratification. With the rapidly changing landscape in breast cancer, there is an urgent need to individualize care and identify opportunities where treatments, both surgical and medical, can be safely right sized to improve quality of life without compromising on outcomes.

Mayo Clinic physicians Judy C. Boughey, M.D., division chair of Breast and Melanoma Surgical Oncology and chair of the Mayo Clinic Comprehensive Cancer Center Breast Cancer Disease Group and Matthew Goetz, M.D., Enterprise Deputy Director of Translational Research and Director of Mayo Clinic Breast Cancer SPORE are part of the SimBioSys clinical advisory team to support the ongoing development and validation of these clinical software tools.

Also Read: Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

SimBioSys has recruited a world-class team of scientists, computational biologists, data scientists, and software engineers that are developing software as a medical device cloud-based platform, TumorSightTM, to be used in the clinic during the treatment planning process. The company’s first product on the TumorSight platform, currently under FDA review, takes a patient’s standard of care DCE-MRI imaging to build a custom 3D digital model of their tumor. This innovative tool provides surgical oncologists with 3D spatial visualizations of breast cancer to support more effective surgical planning and patient consultations. Clear 3D “digital twin” renderings instantly display the tumor in the context of auto segmented anatomical structures (skin, vessels, chest, fat, gland and heart).

“In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care,” says Tushar Pandey, co-founder and CEO of SimBioSys. “SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”

SOURCE: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img